3-Hydroxyanthranilic Acid Delays Paralysis in Models of Amyloid-Beta and Polyglutamine Proteotoxicity

Overview

Journal Biomolecules

Publisher MDPI

Specialties Biochemistry
Molecular Biology

Date 2024 May 24

PMID 38786006

Authors

Bradford T Hull

Kayla M Miller

Caroline Corban

Grant Backer

Susan Sheehan

Ron Korstanje

George L Sutphin

Affiliations

Soon will be listed here.

Abstract

Age is the primary risk factor for neurodegenerative diseases such as Alzheimer's and Huntington's disease. Alzheimer's disease is the most common form of dementia and a leading cause of death in the elderly population of the United States. No effective treatments for these diseases currently exist. Identifying effective treatments for Alzheimer's, Huntington's, and other neurodegenerative diseases is a major current focus of national scientific resources, and there is a critical need for novel therapeutic strategies. Here, we investigate the potential for targeting the kynurenine pathway metabolite 3-hydroxyanthranilic acid (3HAA) using expressing amyloid-beta or a polyglutamine peptide in body wall muscle, modeling the proteotoxicity in Alzheimer's and Huntington's disease, respectively. We show that knocking down the enzyme that degrades 3HAA, 3HAA dioxygenase (HAAO), delays the age-associated paralysis in both models. This effect on paralysis was independent of the protein aggregation in the polyglutamine model. We also show that the mechanism of protection against proteotoxicity from HAAO knockdown is mimicked by 3HAA supplementation, supporting elevated 3HAA as the mediating event linking HAAO knockdown to delayed paralysis. This work demonstrates the potential for 3HAA as a targeted therapeutic in neurodegenerative disease, though the mechanism is yet to be explored.

References

Morley J, Brignull H, Weyers J, Morimoto R . The threshold for polyglutamine-expansion protein aggregation and cellular toxicity is dynamic and influenced by aging in Caenorhabditis elegans. Proc Natl Acad Sci U S A. 2002; 99(16):10417-22. PMC: 124929. DOI: 10.1073/pnas.152161099. View

Fraser A, Kamath R, Zipperlen P, Martinez-Campos M, Sohrmann M, Ahringer J . Functional genomic analysis of C. elegans chromosome I by systematic RNA interference. Nature. 2000; 408(6810):325-30. DOI: 10.1038/35042517. View

Leiser S, Jafari G, Primitivo M, Sutphin G, Dong J, Leonard A . Age-associated vulval integrity is an important marker of nematode healthspan. Age (Dordr). 2016; 38(5-6):419-431. PMC: 5266215. DOI: 10.1007/s11357-016-9936-8. View

Irvine G, El-Agnaf O, Shankar G, Walsh D . Protein aggregation in the brain: the molecular basis for Alzheimer's and Parkinson's diseases. Mol Med. 2008; 14(7-8):451-64. PMC: 2274891. DOI: 10.2119/2007-00100.Irvine. View

Jacobs K, Lovejoy D . Inhibiting the kynurenine pathway in spinal cord injury: Multiple therapeutic potentials?. Neural Regen Res. 2018; 13(12):2073-2076. PMC: 6199950. DOI: 10.4103/1673-5374.241446. View

Parrott J, Redus L, Santana-Coelho D, Morales J, Gao X, OConnor J . Neurotoxic kynurenine metabolism is increased in the dorsal hippocampus and drives distinct depressive behaviors during inflammation. Transl Psychiatry. 2016; 6(10):e918. PMC: 5315555. DOI: 10.1038/tp.2016.200. View

Hipp M, Kasturi P, Hartl F . The proteostasis network and its decline in ageing. Nat Rev Mol Cell Biol. 2019; 20(7):421-435. DOI: 10.1038/s41580-019-0101-y. View

Sutphin G, Kaeberlein M . Measuring Caenorhabditis elegans life span on solid media. J Vis Exp. 2009; (27). PMC: 2794294. DOI: 10.3791/1152. View

Kim C, Lee Y, Ong L, Gold M, Kalali A, Sarkar J . Alzheimer's Disease: Key Insights from Two Decades of Clinical Trial Failures. J Alzheimers Dis. 2022; 87(1):83-100. PMC: 9198803. DOI: 10.3233/JAD-215699. View

10.

Masters C, Bateman R, Blennow K, Rowe C, Sperling R, Cummings J . Alzheimer's disease. Nat Rev Dis Primers. 2016; 1:15056. DOI: 10.1038/nrdp.2015.56. View

11.

Krause D, Suh H, Tarassishin L, Cui Q, Durafourt B, Choi N . The tryptophan metabolite 3-hydroxyanthranilic acid plays anti-inflammatory and neuroprotective roles during inflammation: role of hemeoxygenase-1. Am J Pathol. 2011; 179(3):1360-72. PMC: 3157215. DOI: 10.1016/j.ajpath.2011.05.048. View

12.

Lee W, Lee S, Kim M, Park S, Choi I, Choi I . The tryptophan metabolite 3-hydroxyanthranilic acid suppresses T cell responses by inhibiting dendritic cell activation. Int Immunopharmacol. 2013; 17(3):721-6. DOI: 10.1016/j.intimp.2013.08.018. View

13.

Lopez-Otin C, Blasco M, Partridge L, Serrano M, Kroemer G . The hallmarks of aging. Cell. 2013; 153(6):1194-217. PMC: 3836174. DOI: 10.1016/j.cell.2013.05.039. View

14.

Zhang L, Ovchinnikova O, Jonsson A, Lundberg A, Berg M, Hansson G . The tryptophan metabolite 3-hydroxyanthranilic acid lowers plasma lipids and decreases atherosclerosis in hypercholesterolaemic mice. Eur Heart J. 2012; 33(16):2025-34. DOI: 10.1093/eurheartj/ehs175. View

15.

Fallarino F, Grohmann U, Vacca C, Bianchi R, Orabona C, Spreca A . T cell apoptosis by tryptophan catabolism. Cell Death Differ. 2002; 9(10):1069-77. DOI: 10.1038/sj.cdd.4401073. View

16.

Travessa A, Rodrigues F, Mestre T, Ferreira J . Fifteen Years of Clinical Trials in Huntington's Disease: A Very Low Clinical Drug Development Success Rate. J Huntingtons Dis. 2017; 6(2):157-163. DOI: 10.3233/JHD-170245. View

17.

Lopez-Otin C, Blasco M, Partridge L, Serrano M, Kroemer G . Hallmarks of aging: An expanding universe. Cell. 2023; 186(2):243-278. DOI: 10.1016/j.cell.2022.11.001. View

18.

Guillemin G, Brew B, Noonan C, Takikawa O, Cullen K . Indoleamine 2,3 dioxygenase and quinolinic acid immunoreactivity in Alzheimer's disease hippocampus. Neuropathol Appl Neurobiol. 2005; 31(4):395-404. DOI: 10.1111/j.1365-2990.2005.00655.x. View

19.

Knopman D, Amieva H, Petersen R, Chetelat G, Holtzman D, Hyman B . Alzheimer disease. Nat Rev Dis Primers. 2021; 7(1):33. PMC: 8574196. DOI: 10.1038/s41572-021-00269-y. View

20.

Xu J, Murphy S, Kochanek K, Arias E . Mortality in the United States, 2021. NCHS Data Brief. 2023; (456):1-8. View